New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
18:48 EDTNPSP, LMT, KKD, GWRE, SHPG, ZQKOn The Fly: After Hours Movers
UP AFTER EARNINGS: Guidewire (GWRE), up over 1% after reporting better than expected Q3 results and giving guidance on its conference call. ALSO HIGHER: Lockheed Martin (LMT), up fractionally after being awarded a $914.7M Space Fence contract. DOWN AFTER EARNINGS: Quiksilver (ZQK), down 30%... Krispy Kreme Doughnuts (KKD), down 10.5%. ALSO LOWER: NPS Pharmaceuticals (NPSP), down almost 1% after disclosing in a filing that it has not had any communication with Shire (SHPG) concerning a purported acquisition offer.
News For GWRE;LMT;ZQK;KKD;NPSP;SHPG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 5, 2015
08:55 EDTGWREGuidewire selected by RSA Canada for claims management system
Subscribe for More Information
May 4, 2015
08:52 EDTSHPGShire deserves premium valuation, says Susquehanna
Susquehanna said Shire deserves its premium valuation as it continues to deliver solid performance from marketed products while investing for longer-term growth from its pipeline. Susquehanna reiterated its Positive rating and $290 price target on Shire shares.
07:26 EDTSHPGWorldwide Business Research to hold a conference
BioNetwork East 2015 Partnering Conference is being held in Miami on May 4-6.
07:02 EDTSHPGShire and the Foundation Fighting Blindness announce agreement
Shire and the Foundation Fighting Blindness announced a new agreement focused on furthering research for a novel treatment for autosomal dominant retinitis pigmentosa, or adRP, a rare genetic disease that usually first occurs in late childhood or adolescence and is followed by the progressive loss of peripheral vision. There are no currently approved treatment options for adRP. As part of the agreement, the Foundation Fighting Blindness and its research partners will provide Shire with expert knowledge and scientific background regarding adRP, as well as pertinent clinical information that could be useful in the development of a drug to treat adRP. Shire is compensating the Foundation Fighting Blindness for its considerable expertise in early-stage drug discovery and development, as well as making available it significant expertise and experience with the submission of investigational new drug applications.
May 1, 2015
12:26 EDTSHPGBiogen patent challenged by Kyle Bass
The Coalition For Affordable Drugs, a group linked to Hayman Capital's Kyle Bass, has requested an Inter Partes Review of Claims 1-20 of US patent 8,399,514 held by Biogen (BIIB), according to a USPTO filing. The patent is related to the company's multiple sclerosis drug. BACKGROUND: Previously, the same coalition requested an Inter Partes Review of patents held by Celgene (CELG), Pharmacyclics (PCYC), Acorda Therapeutics (ACOR), Shire (SHPG) and Jazz Pharmaceuticals (JAZZ). PRICE ACTION: Shares of Biogen are up 3% to $385.29 in afternoon trading.
10:20 EDTSHPGShire management to meet with Jefferies
Subscribe for More Information
08:44 EDTSHPGShire price target raised to $298 from $262 at SunTrust
Subscribe for More Information
April 30, 2015
07:09 EDTSHPGShire reaffirms 2015 EPS growth outlook of mid-single digits
Shire said, "We've made a strong start to 2015, and remain confident in delivering Non GAAP diluted earnings per ADS growth in the mid-single digits in 2015. On a Constant Exchange Rate basis we continue to expect product sales growth in the mid-to-high single digits. When excluding INTUNIV, we anticipate low double digit product sales growth on a CER basis. Based on current exchange rates we anticipate low-to-mid single digit product sales growth in 2015, as we expect growth to be held back three to four percentage points by foreign exchange headwinds which particularly impact ELAPRASE, REPLAGAL and VPRIV sales. We expect to see a lower rate of product sales growth through the remainder of 2015 than we've delivered in the first quarter, principally due to stronger comparatives. Royalties and other revenues are expected to increase by 30-40% in 2015, as we include NPS's royalty streams for the first time. Our Non GAAP gross margin is expected to be in line with 2014."
07:08 EDTSHPGShire reports Q1 adjysted EPS $2.84, consensus $2.61
Subscribe for More Information
07:06 EDTSHPGShire appoints Jeff Poulton as CFO
Subscribe for More Information
April 29, 2015
10:00 EDTSHPGOn The Fly: Analyst Initiation Summary
Subscribe for More Information
05:33 EDTSHPGShire initiated with an Outperform at Exane BNP Paribas
Subscribe for More Information
April 28, 2015
17:36 EDTLMTLockheed Martin awarded $142.68M government contract
Lockheed Martin is being awarded a $142.68M modification to a previously awarded cost-plus-incentive-fee contract to continue development of the Joint Strike Fighter Autonomics Logistics Information System Standard Operating Unit Version 2 capability development effort. This modification includes the incorporation of sub-squadron reporting, dynamic routing, and decentralized maintenance capabilities. Work is expected to be completed in July 2017. Fiscal 2015 research, development, test and evaluation funds in the amount of $18.58M will be obligated at time of award, none of which will expire at the end of the current fiscal year.
11:12 EDTLMTNorthrop Grumman to supply navigation system for SBIRS GEO-6 satellite
Northrop Grumman (NOC) has been selected by Lockheed Martin (LMT) to provide the space inertial reference system for the U.S. Air Force's sixth Space Based Infrared System Geosynchronous Earth Orbit satellite. Northrop Grumman will provide its Scalable Space Inertial Reference Unit for sensor pointing/stabilization and attitude control on the SBIRS GEO-6 space vehicle. Northrop Grumman has also provided its Scalable SIRU™ for previous SBIRS GEO satellites, including GEO-5 following the 2014 contract award.
05:54 EDTLMTLockheed Martin awarded contract by Arabsat and KACST
Subscribe for More Information
April 27, 2015
09:04 EDTLMTLockheed Martin awarded contracts totaling $80M
Lockheed Martin continues to advance C-130 aircrew and maintenance training under recent contract awards from the U.S. Air Force valued at more than $80M. Contracts include the delivery of the following training solutions: A C-130J Air Mobility Command, or AMC, weapon systems trainer and C-130J AMC loadmaster part task trainer at Yokota Air Base in Yokota, Japan; A KC-130J weapons systems trainer, spares, support equipment and technical data; C-130 aircrew training system operations and maintenance services; and C-130J Training System Support Center services.
April 23, 2015
09:20 EDTSHPGCelgene patent latest to be challenged by Hayman Capital's Bass
The Coalition For Affordable Drugs, a group linked to Hayman Capital's Kyle Bass, has requested an Inter Partes Review of Claims 1–10 of U.S. Patent No. 6,045,501 held by Celgene (CELG), according to a USPTO filing. The ’501 patent claims methods for delivering a drug, including a teratogenic drug, to a patient while preventing the exposure of a fetus or other contraindicated individuals to the drug. The patent is related to the company's Revlimid drug. BACKGROUND: Previously, the same coalition requested an Inter Partes Review of patents held by Pharmacyclics (PCYC), Acorda Therapeutics (ACOR), Shire (SHPG) and Jazz Pharmaceuticals (JAZZ). On January 7, Reuters reported that Bass planned to take "around 15 pharmaceutical companies with a combined market capitalization of $450B" into an Inter Partes Review for extending patents in questionable ways, citing a presentation made by Bass in Oslo. PRICE ACTION: Shares of Celgene are down 0.5% to $114.92 in pre-market trading.
April 22, 2015
16:31 EDTZQKRyan Drexler calls for Quiksilver to immediately explore options to sell company
Subscribe for More Information
07:07 EDTSHPGEuropean Association for the Study of the Liver to hold annual meeting
50th Annual Meeting of EASL will be held in Vienna, Austria on April 22-26.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use